167 related articles for article (PubMed ID: 32880228)
1. Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study.
Endo Y; Koga T; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
Scand J Rheumatol; 2021 Jan; 50(1):15-19. PubMed ID: 32880228
[No Abstract] [Full Text] [Related]
2. Association of anti-Ro/SSA antibody with response to biologics in patients with rheumatoid arthritis.
Hagiwara S; Tsuboi H; Honda F; Takahashi H; Kurata I; Ohyama A; Yagishita M; Abe S; Kurashima Y; Kaneko S; Kawaguchi H; Takahashi H; Ebe H; Yokosawa M; Asashima H; Hirota T; Umeda N; Kondo Y; Matsumoto I; Sumida T
Mod Rheumatol; 2016 Nov; 26(6):857-862. PubMed ID: 26873159
[TBL] [Abstract][Full Text] [Related]
3. High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
Lee JS; Ahmad H; Shim SC; Bae SC; Song YW; Lee EY
Patient; 2019 Jun; 12(3):319-326. PubMed ID: 30484084
[TBL] [Abstract][Full Text] [Related]
4. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
5. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL
Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
[TBL] [Abstract][Full Text] [Related]
6. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.
D'Agostino MA; Wakefield RJ; Berner-Hammer H; Vittecoq O; Filippou G; Balint P; Möller I; Iagnocco A; Naredo E; Østergaard M; Boers M; Gaillez C; Van Holder K; Le Bars M;
Ann Rheum Dis; 2016 Oct; 75(10):1763-9. PubMed ID: 26590174
[TBL] [Abstract][Full Text] [Related]
7. Anti-Ro (SSA) antibodies in rheumatoid arthritis patients with gold-induced side effects.
Tishler M; Nyman J; Wahren M; Yaron M
Rheumatol Int; 1997; 17(4):133-5. PubMed ID: 9440142
[TBL] [Abstract][Full Text] [Related]
8. Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjögren's syndrome: data from a nationwide cohort for Sjögren's syndrome in Korea.
Park Y; Lee J; Koh JH; Sung YK; Lee SS; Choe JY; Shim SC; Kim JM; Kwon SR; Kim HO; Chung SH; Park SH; Kwok SK
Clin Exp Rheumatol; 2019; 37 Suppl 118(3):107-113. PubMed ID: 31376264
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
[TBL] [Abstract][Full Text] [Related]
10. Isotype switching and titer variation of anti-Ro/SSA antibodies over time in 100 patients with undifferentiated connective tissue disease (UCTD).
Ceribelli A; Cavazzana I; Franceschini F; Quinzanini M; Rizzini FL; Cattaneo R
Clin Exp Rheumatol; 2008; 26(1):117-20. PubMed ID: 18328157
[TBL] [Abstract][Full Text] [Related]
11. Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA.
Chen PK; Lan JL; Chen YM; Chen HH; Chang SH; Chung CM; Rutt NH; Tan TM; Mamat RNR; Anuar ND; Blackburn JM; Chen DY
J Immunol Res; 2021; 2021():6656121. PubMed ID: 33763493
[TBL] [Abstract][Full Text] [Related]
12. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
Kim SK; Choe JY; Park SH; Lee H
Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S
Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281
[TBL] [Abstract][Full Text] [Related]
14. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
[TBL] [Abstract][Full Text] [Related]
15. Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study.
Di Carlo M; Salaffi F; Gremese E; Iannone F; Lapadula G; Ferraccioli G;
Eur J Intern Med; 2019 Aug; 66():57-61. PubMed ID: 31113709
[TBL] [Abstract][Full Text] [Related]
16. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
Alten R; Mariette X; Flipo RM; Caporali R; Buch MH; Patel Y; Marsal S; Sanmartí R; Nurmohamed MT; Griffiths H; Peichl P; Bannert B; Chartier M; Connolly SE; Lozenski K; Rauch C
Clin Rheumatol; 2022 Aug; 41(8):2361-2373. PubMed ID: 35536413
[TBL] [Abstract][Full Text] [Related]
17. Body mass index and response to abatacept in rheumatoid arthritis.
Gardette A; Ottaviani S; Sellam J; Berenbaum F; Lioté F; Fautrel B; Palazzo E; Meyer A; Sibilia J; Dieudé P
Eur J Clin Invest; 2016 Dec; 46(12):1048-1052. PubMed ID: 27736006
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of anti-Ro(SSA) antibody in rheumatoid arthritis.
Boire G; Ménard HA
J Rheumatol; 1988 Mar; 15(3):391-4. PubMed ID: 3259983
[TBL] [Abstract][Full Text] [Related]
19. Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis.
Hirose W; Harigai M; Amano K; Hidaka T; Itoh K; Aoki K; Nakashima M; Nagasawa H; Komano Y; Nanki T;
Arthritis Res Ther; 2021 Aug; 23(1):228. PubMed ID: 34465391
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy outcome and anti-Ro/SSA in autoimmune diseases: a retrospective cohort study.
Mavragani CP; Dafni UG; Tzioufas AG; Moutsopoulos HM
Br J Rheumatol; 1998 Jul; 37(7):740-5. PubMed ID: 9714349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
